Login to Your Account



In the clinic


Friday, August 29, 2014
Oncomed Pharmaceuticals Inc., of Redwood City, Calif., said the FDA removed the partial clinical hold on enrollment in the firm's vantictumab (anti-Fzd7, OMP-18R5) phase I trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription